Zydus Cadila gets tentative nod from USFDA for Brexpiprazole tablets

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

61
USFDA
Picture: Pixabay

Last Updated on September 11, 2021 by The Health Master

Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Brexpiprazole tablets in the strength of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, the company notified via a statement.

The statement also said that Brexpiprazole is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of Major Depressive Disorder (MDD) and for treatment of schizophrenia.

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.

USFDA to review use of Blood Disorder Therapy in children

Aleor gets USFDA final approval for Metronidazole gel

Dr Reddy’s Labs gets USFDA nod for generic Librax capsules

Granules India gets Health Canada nod for drug for Arthritis pain

Sun Pharma gets exclusive right for Winlevi acne cream in US,…

Aurobindo Pharma gets USFDA nod for cancer treatment drug

New laws to be framed for Drugs, Cosmetics, Medical Devices

Govt may impose anti dumping duty on import of vitamin C…

USFDA to review use of Blood Disorder Therapy in children

B-Hub: Biopharma Hub to come up at Hyderabad’s Genome Valley

DCGI grants EUA to Truenat for Nipah virus tests in India

Latest Notifications regarding Pharmaceuticals

Telegram
WhatsApp
Facebook
LinkedIn
Google-news

Enter your email address:

Delivered by FeedBurner